by Admin | Nov 4, 2021 | Portfolio News
– Financing round was co-led by GordonMD Global Investment LP – Funding will support the Phase 2b clinical program of ATI-2173 in HBV MENDHAM, N.J., Nov. 3, 2021 /PRNewswire/ — Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical...
by Admin | Sep 22, 2021 | Portfolio News
三叶草新冠候选疫苗的全球2/3期临床试验结果显示对德尔塔 (Delta) 变异株的保护效力为79% 在全球四大洲的 “ SPECTRA” 2/3期临床试验共入组了超过30,000 名成年和老年受试者，在保护效力分析中100% 的SARS-CoV-2（新冠病毒）均为变异株（Delta变异株为主）临床试验成功达到疫苗保护效力的主要终点及次要终点“...
by Admin | Jul 28, 2021 | Portfolio News
SHANGHAI, July 28, 2021 /PRNewswire/ — Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced the initiation of a Phase 1a clinical trial evaluating ECC0509, an oral...
by Admin | Jul 16, 2021 | Portfolio News
Imperative Care to Create Strategic Network of Wholly Owned Development Subsidiaries in Areas of Synergy, Starting with Acquisition of Truvic Medical, Inc., a Peripheral Thrombectomy Innovator July 15, 2021 08:00 AM Eastern Daylight Time CAMPBELL,...
by Admin | Jul 7, 2021 | Portfolio News
SPECTRA enrolled over 29,000 adult and elderly participants across four continents achieving high ethnic diversity and robust dataset of circulating strainsRelease of vaccine efficacy data anticipated in Q3 2021 and will include sequencing data of SARS-CoV-2 variants...
by Admin | Jun 30, 2021 | Portfolio News
MENDHAM, N.J. and WARMINSTER, Pa., – Antios Therapeutics, Inc. and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination of Arbutus’ proprietary GalNAc...
